Notably, it has been reported that UBE2C downregulates p53 expression in endometrial cancer[16], indicating that UBE2C may be involved in regulating the drug resistance of glioma through modulating the p53/glycolysis axis. This evidence concerns the gene UBE2C and endometrial cancer.